Takayasu’s arteritis

1. High-Yield Summary

• Takayasu arteritis (pulseless disease) is a chronic granulomatous panarteritis of the elastic large arteries, predominantly affecting the aorta, its primary branches (brachiocephalic, common carotid, subclavian, renal), and pulmonary arteries in young women (female-to-male ratio 8:1 to 9:1, peak onset between 15 and 35 years).
• Cardinal diagnostic benchmarks include asymmetric bilateral upper extremity blood pressures (systolic delta greater than 10 to 15 mmHg), diminished or absent peripheral pulses (especially radial and brachial), audible arterial bruits (subclavian, carotid, abdominal aorta), and exertional arm claudication that can masquerade as thoracic outlet syndrome, cervical radiculopathy, or rotator cuff tendinopathy.
• Non-invasive magnetic resonance angiography (MRA) with black-blood vessel wall imaging is the gold-standard modality to visualize early mural edema, circumferential wall thickening, and late gadolinium enhancement before fixed luminal stenosis or occlusions manifest, while eliminating ionizing radiation in young females.
• High-dose systemic glucocorticoids combined with early non-glucocorticoid immunosuppressive agents (methotrexate, azathioprine, or biologics including tocilizumab and tumor necrosis factor inhibitors) form the cornerstone of medical remission induction and maintenance.
• Elective vascular revascularization (open surgical bypass or endovascular intervention) is strictly contraindicated during active arterial inflammation except in emergent limb- or organ-threatening ischemia; procedures performed during active vasculitis suffer high rates of anastomotic dehiscence, pseudoaneurysm formation, thrombosis, and rapid in-stent restenosis.

2. Anatomy

Takayasu arteritis displays a marked predilection for the elastic proximal arterial tree, involving the thoracic and abdominal aorta and its major direct branches. Anatomic understanding of the vascular hierarchy and surrounding neurovascular relationships is paramount for physical diagnosis and surgical planning.

• Subclavian and Axillary Artery Anatomy: The left subclavian artery arises directly from the aortic arch, whereas the right subclavian artery branches from the brachiocephalic (innominate) trunk. Each vessel arches across the superior thoracic aperture and traverses the interscalene triangle between the anterior scalene muscle anteriorly and middle scalene muscle posteriorly, situated directly adjacent to the upper, middle, and lower trunks of the brachial plexus. At the lateral border of the first rib, the subclavian artery transitions into the axillary artery. Transmural periadventitial inflammation in Takayasu arteritis frequently obliterates normal surgical tissue planes, causing dense fibrous adherence of the vessel wall to adjacent brachial plexus trunks and the prevertebral fascia.
• Carotid and Cervical Corridors: The common carotid arteries ascend through the neck within the carotid sheath, medial to the internal jugular vein and anterior to the vagus nerve (cranial nerve X). The bifurcation into internal and external carotid arteries occurs at the C3-C4 vertebral level. Transmural carotid involvement causes carotidynia, localized tenderness on palpation over the carotid bulb that can mimic anterior cervical disc pathology or thyroiditis.
• Abdominal and Visceral Aortic Branches: The disease frequently involves the thoracoabdominal aorta, celiac axis, superior mesenteric artery, and bilateral renal arteries. Luminal compromise of the renal arteries leads to marked secondary renovascular hypertension via renin-angiotensin-aldosterone axis activation.

Critical neurovascular danger zones and surgical intervals must be respected during diagnostic exposure and revascularization:

• Vertebral Artery Takeoff: The vertebral artery arises from the posterosuperior aspect of the first portion of the subclavian artery. Critical stenosis proximal to this takeoff generates subclavian steal syndrome, wherein exercise-induced vasodilation of the ipsilateral upper extremity reverses blood flow down the ipsilateral vertebral artery, siphoning flow from the basilar system and causing exercise-induced syncope, ataxia, or visual loss.
• Recurrent Laryngeal Nerve: On the left, the recurrent laryngeal nerve loops under the aortic arch immediately distal to the ligamentum arteriosum; on the right, it loops beneath the first segment of the subclavian artery. Chronic periadventitial scarring and inflammatory tissue friability place this nerve at high risk for traction or thermal injury during proximal exposure.
• Phrenic Nerve: Runs vertically down the anterior surface of the anterior scalene muscle within its investing prevertebral fascia, directly anterior to the subclavian artery. In aggressive supraclavicular dissections or decompressive procedures, failure to mobilize the phrenic nerve safely results in diaphragmatic hemiparalysis.
• Internervous Intervals: Standard surgical corridors include the supraclavicular exposure utilizing the intermuscular interval between the sternocleidomastoid (spinal accessory nerve, CN XI) and the trapezius/omohyoid, and the deltopectoral interval between the deltoid (axillary nerve) and pectoralis major (medial and lateral pectoral nerves) to reach the axillary and distal subclavian vessels safely.

3. Pathogenesis

The pathogenesis of Takayasu arteritis is characterized by an autoimmune cell-mediated granulomatous panarteritis. While the exact trigger remains unelucidated, robust genetic associations have been validated across diverse populations, particularly with human leukocyte antigen (HLA) alleles HLA-B*52 and HLA-B*67, as well as genetic polymorphisms in the interleukin-12B (IL-12B) and MLX loci.

The immunological and cellular sequence progresses through well-defined biological phases:

• Cell-Mediated Vascular Infiltration: Circulating T lymphocytes (specifically gamma-delta T cells, CD4+ T helper 1 [Th1] cells, and CD8+ cytotoxic T cells) infiltrate the arterial wall via the adventitial vasa vasorum. Cytotoxic T cells release perforin and granzyme B, inducing vascular smooth muscle cell and endothelial cell apoptosis.
• Granuloma Formation and Elastophagy: Infiltrating Th1 and Th17 lymphocytes secrete pro-inflammatory cytokines, including interferon-gamma (IFN-gamma), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha). These signals activate macrophages, which coalesce into multinucleated Langhans giant cells within the tunica media. The activated macrophages release matrix metalloproteinases (MMP-2, MMP-9) that digest the internal and external elastic laminae (elastophagy), stripping the arterial wall of its structural elasticity.
• Destructive vs. Fibrotic Remodeling: Destruction of the muscular and elastic architecture in the tunica media reduces tensile strength. Under physiological arterial pressure, weakened segments undergo post-stenotic dilation, ectasia, or frank saccular and fusiform aneurysm formation. Concurrently, chronic inflammation stimulates platelet-derived growth factor (PDGF) and transforming growth factor-beta (TGF-beta), driving profound myofibroblast migration and adventitial fibrosis. This leads to marked concentric intimal fibrocellular hyperplasia, luminal narrowing, and segmental thrombosis.

4. Natural History

Takayasu arteritis exhibits an annual incidence of 1 to 2 cases per million individuals in Western populations, with a considerably higher prevalence documented in East Asian, South Asian, and Latin American cohorts. Women of reproductive age represent approximately 85% to 90% of affected patients, with typical clinical onset occurring between 15 and 35 years of age.

The natural course of the disease follows an insidious, biphasic or triphasic progression:

• Pre-Pulseless Inflammatory Phase: Begins with non-specific constitutional features, including low-grade intermittent pyrexia, malaise, fatigue, night sweats, weight loss, and widespread inflammatory polyarthralgias or myalgias. Because vascular occlusions have not yet matured, peripheral pulses remain palpable, and blood pressures are symmetrical. Consequently, diagnostic delay in this early phase frequently averages 12 to 36 months.
• Vascular Occlusive and Stenotic Phase: As transmural inflammation progresses to luminal fibrosis, manifestations of peripheral and visceral ischemia dominate. Patients present with asymmetric limb claudication, cold extremities, diminished or absent pulses, renovascular hypertension, cerebral hypoperfusion, or exertional angina.
• Burned-Out or Quiescent Phase: Active inflammation subsides into chronic, fixed fibrotic scarring. However, patients remain at permanent risk of secondary hemodynamic compromise, congestive heart failure from aortic insufficiency, late aneurysm rupture, and ischemic stroke.

Long-term prognosis correlates directly with the development of major secondary vascular complications. The validated Ishikawa prognostic classification identifies four catastrophic disease complications: severe secondary hypertension, severe aortic regurgitation, thoracic or abdominal aortic aneurysms, and severe ischemic retinopathy. Patients presenting without these complications experience a 5-year event-free survival rate exceeding 95%. Conversely, patients presenting with two or more major complications suffer 5-year survival rates below 60%, with mortality primarily driven by heart failure, stroke, and ruptured aneurysms.

5. Clinical Presentation

History

Clinicians must maintain high suspicion when young adult females present with persistent upper limb complaints accompanied by constitutional or systemic symptoms. Essential history components include:

• Exertional Upper Extremity Symptoms: Severe ache, heaviness, fatigue, cramping, or paresthesias in the arm provoked by repetitive overhead work, typing, or exercise, rapidly relieved by rest. This exertional vascular claudication is frequently misdiagnosed by orthopaedic clinicians as thoracic outlet syndrome, cervical spine disease, or rotator cuff pathology.
• Cervical Pain (Carotidynia): Unilateral or bilateral neck tenderness radiating to the mandible or mastoid process, aggravated by swallowing or neck extension, reflecting active carotid artery wall inflammation.
• Cerebrovascular and Ocular Disturbances: Postural dizziness, lightheadedness, syncope, transient ischemic attacks (TIAs), transient monocular vision loss (amaurosis fugax), or visual field deficits related to common carotid or vertebral arterial stenoses.
• Systemic and Visceral Symptoms: Unexplained exertional chest pain (coronary ostial involvement), progressive dyspnea (aortic root dilation with regurgitation or pulmonary hypertension), postprandial abdominal angina (mesenteric ischemia), and headaches refractory to conventional analgesics.

Physical Exam

A rigorous, bilateral four-limb physical and vascular examination is the absolute diagnostic cornerstone:

• Four-Limb Blood Pressure Discrepancy: Measurement of blood pressure across both upper and lower extremities. A systolic difference greater than 10 mmHg between arms is abnormal; a delta greater than 20 mmHg strongly suggests subclavian or axillary artery stenosis.
• Pulse Quality and Symmetry: Palpation of radial, brachial, common carotid, femoral, posterior tibial, and dorsalis pedis pulses. Attenuated, delayed, or absent upper extremity pulses are classic.
• Vascular Auscultation: Careful auscultation over the supraclavicular spaces (subclavian bruits), anterior cervical triangles (carotid bruits), epigastrium (abdominal aortic bruits), and flank regions (renal artery bruits).
• Cardiac and Neurological Exam: Auscultation of early diastolic decrescendo murmurs at the right upper sternal border indicating aortic insufficiency; comprehensive cranial nerve and sensory motor testing to document ischemic deficits.

6. Imaging and Diagnostic Studies

Modern imaging has revolutionized the diagnosis and surveillance of Takayasu arteritis, shifting the paradigm from visualizing late luminal stenosis to detecting early, reversible vessel wall inflammation.

• Magnetic Resonance Angiography (MRA) – Gold Standard: MRA combining 3D contrast-enhanced luminal reconstructions with high-resolution black-blood vessel wall imaging is the primary diagnostic modality. It visualizes circumferential vessel wall thickening, mural edema (T2-weighted hyperintensity), and mural late gadolinium enhancement indicating active transmural vascular inflammation. Importantly, MRA avoids ionizing radiation, making it the preferred serial monitoring tool for young patients.
• 18F-Fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET/CT): Detects active vascular wall glucose metabolism in infiltrating leukocytes. Vascular wall uptake greater than or equal to liver uptake confirms active large-vessel vasculitis. PET/CT is particularly sensitive for detecting disease in early pre-stenotic stages and appraising systemic metabolic remission during immunosuppressive therapy.
• Computed Tomography Angiography (CTA): Provides rapid, isotropic, sub-millimeter anatomical detail of the entire arterial tree. Characteristic CTA findings include smooth, concentric arterial wall thickening (the “double-ring” sign on venous phase contrast images), luminal narrowing, aneurysms, and vascular calcifications. However, cumulative radiation exposure limits its serial utility in young women.
• Color Doppler Ultrasound: Effective for evaluating superficial, accessible vessels, specifically the common carotid, subclavian, axillary, and femoral arteries. The pathognomonic ultrasound sign is the “macaroni sign”: smooth, concentric, homogeneous hypoechoic arterial wall thickening without calcified atherosclerotic plaques, accompanied by luminal narrowing and hemodynamic acceleration.
• Catheter-Directed Digital Subtraction Angiography (DSA): Historically the reference standard for luminal mapping. However, DSA only delineates the vascular lumen and cannot evaluate the vessel wall or active mural inflammation. Today, DSA is strictly reserved for therapeutic endovascular revascularization.
• Laboratory Evaluation: Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are elevated in 70% to 80% of active cases. Crucially, up to 30% of patients with histologically proven active vasculitis demonstrate completely normal ESR and CRP levels, emphasizing that normal inflammatory markers do not exclude active disease. Serological markers (ANA, RF, ANCA) are characteristically negative, aiding in differentiation from systemic lupus erythematosus and ANCA-associated vasculitis.

7. Classification

Two validated classification systems govern the anatomical staging and diagnostic categorization of Takayasu arteritis:

1. Hata / Numano Angiographic Classification System: Categorizes the anatomical distribution of arterial involvement based on cross-sectional or catheter angiography, providing critical guidance for surgical and interventional exposure:

Note: Involvement of coronary (C+) or pulmonary (P+) arteries is recorded as a phenotypic modifier (e.g., Type V[P+]).

2. 2022 ACR / EULAR Classification Criteria for Takayasu Arteritis: Established to improve diagnostic specificity in clinical practice and trials, requiring an absolute entry criterion of age 60 years or younger at diagnosis with confirmed large-vessel vasculitis on imaging, followed by weighted scoring:

Diagnostic Threshold: A cumulative score of 5 or more points yields a diagnostic sensitivity of 93.8% and specificity of 98.8%.

8. Treatment

Medical / Nonoperative

Medical immunosuppressive therapy is the first-line foundation for all patients diagnosed with active Takayasu arteritis, aimed at inducing clinical and serological remission, terminating mural inflammation, and preventing irreversible luminal stenosis or aneurysm expansion.

• Glucocorticoid Induction: High-dose oral prednisone (0.5 to 1.0 mg/kg/day, typically 40 to 60 mg/day) is initiated immediately. In cases of acute, vision-threatening, cerebral, or critical limb ischemia, intravenous pulse methylprednisolone (1,000 mg/day for 3 consecutive days) is administered. Once disease control is achieved, corticosteroids are tapered gradually over 6 to 12 months toward a target maintenance dose below 10 mg/day.
• Non-Glucocorticoid Immunosuppressive Therapy: In accordance with international consensus guidelines, a non-glucocorticoid steroid-sparing agent is initiated concurrently with corticosteroids at diagnosis to minimize cumulative steroid toxicity. First-line conventional synthetic disease-modifying antirheumatic drugs (DMARDs) include subcutaneous methotrexate (15 to 25 mg weekly) or azathioprine (2.0 to 2.5 mg/kg/day). Mycophenolate mofetil (2.0 to 3.0 g/day) and leflunomide (20 mg/day) serve as effective second-line alternatives.
• Biologic Immunomodulation: For patients with relapsing, refractory, or steroid-resistant disease, biologic agents demonstrate profound efficacy. Tocilizumab, an interleukin-6 receptor monoclonal antibody (162 mg subcutaneous weekly or 8 mg/kg IV monthly), significantly reduces relapse frequency and facilitates steroid cessation. Tumor necrosis factor-alpha (TNF-alpha) antagonists (infliximab 5 to 10 mg/kg IV every 4 to 8 weeks, or adalimumab) represent proven alternatives, particularly in young patients with progressive mural thickening.
• Cardiovascular Support: Low-dose aspirin (81 to 100 mg/day) is prescribed to reduce ischemic stroke and thromboembolic risk unless contraindicated. Aggressive blood pressure control is mandatory; however, angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) must be utilized with extreme caution in patients with bilateral renal artery stenosis due to the risk of precipitating acute renal failure. Bone protection (calcium, vitamin D, bisphosphonates) and infection prophylaxis are standard during prolonged immunosuppression.

Operative

The primary goals of vascular intervention are the restoration of vital organ and extremity perfusion and the management of life-threatening aneurysms or aortic regurgitation.

The Quiescence Principle: Revascularization must never be performed during active arterial inflammation except under emergent circumstances. Elective intervention must be deferred until comprehensive clinical, serological (ESR/CRP), and cross-sectional imaging (MRA/PET-CT) quiescence has been achieved for at least 3 to 6 months. Interventions performed during active inflammation carry failure rates exceeding 50%, with high risks of anastomotic rupture, pseudoaneurysm, and acute thrombosis.

• Open Surgical Bypass Grafting: Remains the gold standard for durable long-term revascularization in Takayasu arteritis. Autologous saphenous vein grafts or synthetic PTFE conduits are preferred. Critical surgical technique requires anchoring the proximal and distal anastomoses into macroscopically normal, non-inflamed arterial segments well outside the active zone of vasculitis. Anastomoses must be constructed with pledgeted, non-absorbable monofilament sutures to distribute tension across friable arterial tissue. Common procedures include carotid-subclavian bypass, axillo-axillary bypass, ascending aorta-to-brachiocephalic bypass, and aortorenal bypass.
• Endovascular Interventions (Angioplasty and Stenting): Balloon angioplasty with or without stenting offers a less invasive alternative for focal, short-segment stenoses. Plain balloon angioplasty is preferred over bare-metal stenting in small-caliber vessels due to high rates of in-stent intimal hyperplasia. Balloon-expandable or self-expanding covered stents have selective utility in focal, fibrotic, burned-out stenoses or pseudoaneurysm exclusion. Endovascular approaches have significantly lower long-term patency rates than open bypass, frequently necessitating serial re-interventions.
• Aortic Valve and Root Reconstruction: Indicated for severe aortic regurgitation with progressive left ventricular dilation. Aortic valve replacement often requires composite graft root replacement (Bentall procedure) due to concomitant ascending aortic wall pathology and annular dilatation.

Indications & Contraindications

Absolute Indications for Revascularization:

• Critical upper or lower extremity limb ischemia with resting pain, tissue ulceration, or gangrene.
• Severe cerebrovascular ischemia (recurrent transient ischemic attacks, amaurosis fugax, progressive stroke risk secondary to carotid or vertebral stenosis).
• Refractory secondary renovascular hypertension failing three or more antihypertensive medications, or progressive ischemic renal function decline.
• Aortic aneurysms exceeding 5.5 cm in the ascending aorta, 6.0 cm in the descending thoracic aorta, rapid expansion greater than 5 mm/year, or symptomatic pseudoaneurysms.
• Severe symptomatic aortic regurgitation with left ventricular end-systolic dimension exceeding 50 mm or ejection fraction below 50%.

Contraindications to Revascularization:

• Active arterial inflammation: Elective surgery performed in the setting of elevated ESR/CRP or active mural hyperenhancement on MRA/PET is strictly contraindicated.
• Asymptomatic mild or moderate upper extremity claudication manageable with medical therapy and lifestyle modification.
• Isolated angiographic stenoses without functional hemodynamic compromise or end-organ hypoperfusion.

9. Outcome

Modern multidisciplinary management combining aggressive early immunosuppression with judicious, delayed revascularization has transformed the clinical outcomes of Takayasu arteritis:

• Revascularization Patency Rates: Open surgical bypass demonstrates clear superiority over endovascular therapy in long-term durability. Five-year primary patency rates for open bypass range from 75% to 85%, compared to 40% to 55% for endovascular balloon angioplasty or stenting. Cumulative 5-year secondary patency for open surgical bypass exceeds 90% when performed in specialized centers.
• Impact of Disease Quiescence: Disease activity at the time of intervention represents the single most powerful prognostic determinant of surgical success. When revascularization is performed in biochemically and radiologically quiescent vessels, 5-year patency rates exceed 85%. Conversely, operations conducted during active inflammatory phases display failure rates approaching 60% within 24 months due to anastomotic dehiscence, graft thrombosis, or aggressive neointimal hyperplasia.
• Survival and Quality of Life: Overall 10-year survival in contemporary cohorts ranges between 80% and 90%. Early mortality is predominantly driven by acute myocardial infarction, congestive heart failure, stroke, and aneurysm rupture. More than 80% of patients successfully revascularized for limb claudication experience complete resolution of exertional limb symptoms, enabling return to full occupational and physical activity.

10. Complications

Complications in Takayasu arteritis arise from intrinsic vascular destruction, surgical and endovascular interventions, and prolonged immunosuppression:

11. Pearls and Pitfalls

• The Bilateral Blood Pressure Rule: Routinely obtain bilateral upper extremity manual blood pressures in every young female patient presenting with upper extremity fatigue, arm claudication, or unexplained neck/shoulder discomfort. A systolic difference greater than 10 to 15 mmHg is a clinical red flag for proximal subclavian pathology.
• The Silent Remission Trap: Never rely on normal erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) alone to declare clinical quiescence. Nearly one-third of patients with normal acute-phase reactants have active transmural inflammation on MRA (mural edema and enhancement) or PET-CT. Cross-sectional imaging is mandatory prior to elective surgery.
• The Quiescence Mandate: Do not intervene surgically or endovascularly on an actively inflamed vessel unless forced by acute tissue necrosis or limb loss. Treat the patient with intense immunosuppression first; wait for vascular quiescence to maximize graft patency and prevent pseudoaneurysms.
• Diagnostic Masqueraders: Upper limb exertional claudication in Takayasu arteritis frequently mimics neurogenic thoracic outlet syndrome (TOS) or rotator cuff tendinopathy. Performing first rib resection or shoulder arthroscopy in a patient with undiagnosed Takayasu arteritis can precipitate severe vascular trauma, catastrophic bleeding, or acute thrombosis.
• Pledgeted Anastomoses: When performing open bypass grafting, always use pledgeted, non-absorbable monofilament sutures to distribute tension evenly across the fragile, scarred host artery and prevent suture pull-through.

12. Controversy

• Open Surgical Bypass versus Endovascular Therapy: The comparative utility of open bypass surgery versus endovascular balloon angioplasty and stenting remains an enduring clinical debate. While endovascular interventions offer lower perioperative morbidity, reduced hospital stays, and minimal soft-tissue disruption, their susceptibility to high restenosis rates (exceeding 40% to 50% at 2 years) frequently mandates repeat procedures. Conversely, open surgical bypass demonstrates superior 5-year and 10-year patency, but carries higher upfront surgical invasiveness, particularly in patients with thoracic aortic disease. Current consensus reserves endovascular therapy for focal, short-segment stenoses in quiescent disease or high-risk surgical candidates, while open bypass remains the gold standard for extensive, long-segment occlusions and young, operative candidates.
• Optimal Biologic Strategy (IL-6 Blockade vs. TNF-alpha Inhibition): The choice of first-line biologic therapy in refractory Takayasu arteritis continues to generate debate. Both the interleukin-6 receptor antagonist tocilizumab and TNF-alpha inhibitors (infliximab, adalimumab) have demonstrated marked steroid-sparing efficacy and clinical remission induction. However, because tocilizumab directly suppresses hepatic CRP synthesis regardless of vascular inflammation, serum CRP becomes unreliable as a biomarker of disease activity, raising concerns about occult, smoldering mural disease in patients receiving IL-6 blockade. Prospective head-to-head randomized trials are needed to define optimal biologic selection.
• Surveillance Protocols and Defining True Quiescence: Substantial controversy surrounds the definitive criteria for biological and radiological remission. The lack of concordance between clinical symptom scores (e.g., Birmingham Vasculitis Activity Score, Indian Takayasu Clinical Activity Score), serum inflammatory markers, and advanced vessel wall imaging (MRA late enhancement versus 18F-FDG PET uptake) leaves clinicians without a singular gold-standard definition of quiescence before elective surgical revascularization.

13. Evidence-Based Synthesis

Modern clinical decision-making is grounded in high-quality randomized controlled trials and prospective registry analyses, corroborated by seminal biomechanical and anatomical descriptions.

14. References

• Maz M, Chung SA, Abril A et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Rheumatol. 2021. doi:10.1002/art.41774 [Level I: Systematic Review / Meta-Analysis]
• Dejaco C, Ramiro S, Bond M et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update. Ann Rheum Dis. 2024. doi:10.1136/ard-2023-224543 [Level I: Systematic Review / Meta-Analysis]
• Dejaco C, Ramiro S, Duftner C et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis. 2018. doi:10.1136/annrheumdis-2017-212649 [Level I: Systematic Review / Meta-Analysis]
• Dawn Kleindorfer, Amytis Towfighi, Seemant Chaturvedi et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021. doi:10.1161/str.0000000000000375 [Level V (Expert Conceptual Review): Seminal Conceptual / Observational Study]
• Vicente A. Riambau, D. Böckler, Jan Sigge Brunkwall et al. Editor’s Choice – Management of Descending Thoracic Aorta Diseases. European Journal of Vascular and Endovascular Surgery. 2017. doi:10.1016/j.ejvs.2016.06.005 [Level IV (Prognostic / Case Series): Seminal Conceptual / Observational Study]

15. Master Class Pro-Tip

The cardinal sin in managing Takayasu arteritis is operating on an active vessel. Vascular reconstructive procedures performed during active arterial inflammation are doomed to catastrophic failure rates, including anastomotic dehiscence, rapid in-stent restenosis, and pseudoaneurysm rupture. Unless forced by acute, limb- or life-threatening ischemia, the surgical team must enforce strict multidisciplinary collaboration with rheumatology, achieving complete clinical, serological, and radiologic quiescence on MRA or PET-CT before deploying the scalpel. When revascularization is undertaken, anastomoses must be anchored in healthy arterial beds outside the inflammatory field using pledgeted sutures, and perioperative immunosuppression must be rigorously sustained to prevent surgical trauma from igniting a disease flare.

Master Class Surgical Pearl: Preoperative Quiescence and Vascular Access in Takayasu Arteritis